Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592771 | 0.85 | JAK2 (0.44) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL30239719 | 0.82 | KCNN4 (0.46) | KCNN4ACHEKIF11CYP19A1HDAC3 | |
| SCHEMBL28945248 | 0.82 | KCNN4 (0.46) | KCNN4ACHEKIF11CYP19A1HDAC3 | |
| SCHEMBL26394766 | 0.80 | KCNN4 (0.43) | KCNN4ACHEKIF11CYP19A1HDAC3 | |
| SCHEMBL1625398 | 0.80 | TSHR (0.45) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL10183753 | 0.79 | HDAC4 (0.42) | ACHEJAK2ROCK2PRKCQPRKCD | |
| SCHEMBL12585675 | 0.79 | CYP19A1 (0.38) | CYP19A1 | |
| SCHEMBL18567400 | 0.78 | KCNN4 (0.39) | KCNN4ACHEKIF11CYP19A1HDAC3 | |
| SCHEMBL15693460 | 0.78 | PRKCQ (0.44) | KCNN4ACHEPRKCQKIF11CYP19A1 | |
| SCHEMBL2442297 | 0.78 | ACHE (0.44) | ACHEJAK2ROCK2PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570646-B2 | Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-116033899-B | Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same | 株式会社 钟根堂 | 2024-11-05 | — | — | CN | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230295142-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4208461-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2023-07-12 | — | — | EP | disclosed |
| CN-116033899-A | Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same | 株式会社 钟根堂 | 2023-04-28 | — | — | CN | disclosed |
| WO-2004043355-A2 | ALPHA, ALPHA-DISUBSTITUTED BENZYLGLYCINE DERIVATIVES AS HIV PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| CN-1444570-A | Non-steroidal anti-inflammatory drugs | SCHERING AG (DE) | 2003-09-24 | — | — | CN | disclosed |
| EP-1309571-A1 | NON-STEROIDAL INFLAMMATION INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-14 | — | — | EP | disclosed |
| US-20020077356-A1 | Nonsteroidal antiinflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002010143-A1 | NON-STEROIDAL INFLAMMATION INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | WO | disclosed |
| EP-0912494-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998056752-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1998-12-17 | — | — | WO | disclosed |
| WO-1997046511-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0743853-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021612-A2 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077356-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGES2, PTGES | KCNN4 2828/4885ACHE 1330/4885JAK2 2334/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KCNN4 4456/4885ACHE 4291/4885JAK2 859/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | KCNN4 4452/4885ACHE 4286/4885JAK2 880/4885 |
| US-20230295142-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC2 | KCNN4 4851/4885ACHE 3920/4885JAK2 1472/4885 |
| US-12570646-B2 | Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | HDAC6, HDAC3, HDAC1 | KCNN4 3960/4885ACHE 2970/4885JAK2 1930/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KCNN4 4456/4885ACHE 4291/4885JAK2 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.